TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37560813

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with dose reduction in patients ≤55 years old after achieving complete metabolic response (CMR)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Immunochemotherapy with standard dose (BURKIMAB08 trial)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (BURKIMAB14 trial)
Number of subjects: 107
Study: 37560967

Group type: EXPERIMENTAL
Intervention: ORBCEL-M (80×10^6 cells)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ORBCEL-M
Number of subjects: 16
Study: 37561058

Group type: EXPERIMENTAL
Intervention: TAF 25 mg once daily
Number of subjects: 1298

Group type: COMPARATOR
Intervention: TDF 300 mg once daily (followed by TAF after 2 or 3 years)
Number of subjects: 1298
Study: 37561087

Group type: EXPERIMENTAL
Intervention: Microencapsulated watermelon rind (WR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Microencapsulated watermelon rind with beetroot (WR + B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 37561246

Group type: EXPERIMENTAL
Intervention: Epicardial GP ablation with pulsed field (PF) during CABG
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Holter monitoring post-procedure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Post-operative AF observation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) assessment
Number of subjects: 24
Study: 37561249

Group type: EXPERIMENTAL
Intervention: Orbital radiotherapy (OR) with a total dose of 20 Gy, divided into 10 sessions of 2 Gy each, with concomitant oral intake of low-dose glucocorticoids.
Number of subjects: 26
Study: 37561269

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonsurgical controls
Number of subjects: 16
Study: 37561355

Group type: EXPERIMENTAL
Intervention: Dual-task program (balance and cognitive), 3 days per week for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional physical therapy
Number of subjects: 30
Study: 37561451

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab without chemotherapy (group A)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Pertuzumab plus trastuzumab with chemotherapy (group B)
Number of subjects: 210
Study: 37561461

Group type: EXPERIMENTAL
Intervention: Fluid-corrected AKI diagnosis
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Fluid-corrected AKI
Number of subjects: 923
Study: 37561558

Group type: EXPERIMENTAL
Intervention: Virtual meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Real meal
Number of subjects: 20
Study: 37561571

Group type: EXPERIMENTAL
Intervention: Smart Girlfriend program
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Control intervention (1-page information sheet on condom use)
Number of subjects: 10000
Study: 37561579

Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 19

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 19
Study: 37561748

Group type: EXPERIMENTAL
Intervention: Tdap and COVID-19 vaccination rates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gestational diabetes screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Length of post-partum hospital stay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Onset of depression, anxiety, and adjustment disorder
Number of subjects: 0
Study: 37561967

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 77
Study: 37562004

Group type: EXPERIMENTAL
Intervention: OAsIs combination therapy (targeted therapies against CD20, BCL2, and Bruton tyrosine kinase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MALT1 protease inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CARD11 gain of function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 16-gene resistance signature
Number of subjects: 0
Study: 37562003

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 391
Study: 37562051

Group type: EXPERIMENTAL
Intervention: Recombinant ACE2-P18F3
Number of subjects: 0
Study: 37562063

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin/relebactam (maximum dose of 15 mg/kg imipenem and 15 mg/kg cilastatin, 7.5 mg/kg relebactam)
Number of subjects: 46
Study: 37562095

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg BID or 1500 mg BID) combined with platinum-based chemoradiation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metformin compliance ≥70%
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 25
Study: 37562120

Group type: EXPERIMENTAL
Intervention: TOKA personalised HTO system
Number of subjects: 25
Study: 37562195

Group type: EXPERIMENTAL
Intervention: HER2-low (IHC 1+ or IHC 2+/ISH-)
Number of subjects: 789
Study: 37562641

Group type: EXPERIMENTAL
Intervention: BI 1026706 100 mg bid
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 37562757

Group type: EXPERIMENTAL
Intervention: Surefil one™ Self-Adhesive bulk-fill resin composite
Number of subjects: 83

Group type: COMPARATOR
Intervention: Filtek™ Bulk-Fill posterior composites
Number of subjects: 83
Study: 37562791

Group type: EXPERIMENTAL
Intervention: nCLE imaging of granulomas
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: nCLE imaging of lung nodules
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: nCLE imaging of lymph nodes
Number of subjects: 25
Study: 37562934

Group type: EXPERIMENTAL
Intervention: Codesigned complex intervention to prevent pressure ulcers, malnutrition, poor oral health and falls
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Codesigned complex intervention
Number of subjects: 16
Study: 37563004

Group type: EXPERIMENTAL
Intervention: Eliapixant 125 mg twice daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 37563240

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab combined with mFOLFOX6 chemotherapy
Number of subjects: 57
Study: 37563313

Group type: EXPERIMENTAL
Intervention: Stereotactic thermal ablation with CT during hepatic arteriography (CTHA) imaging and computer-based software assessment of ablation margins
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stereotactic thermal ablation
Number of subjects: 50
Study: 37563553

Group type: EXPERIMENTAL
Intervention: Device-based movement intervention (activPAL and StepWatch)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 50
Study: 37563568

Group type: EXPERIMENTAL
Intervention: hrBMP4 (0.5 to 18 mg)
Number of subjects: 15
Study: 37563595

Group type: EXPERIMENTAL
Intervention: SMS system to support a culturally-adapted Diabetes Prevention Program (DPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMS system
Number of subjects: 0
Study: 37563608

Group type: EXPERIMENTAL
Intervention: Esperanza extract (Petiveria alliacea)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 0
Study: 37563665

Group type: EXPERIMENTAL
Intervention: TreC Diabete platform as part of their personalised care plan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 37563914

Group type: EXPERIMENTAL
Intervention: Flunarizine with add-on Alpha-Lipoic Acid (ALA)
Number of subjects: 60
Study: 37564370

Group type: EXPERIMENTAL
Intervention: Therapeutic SCiP™ therapy for 8 weeks (G2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham stimulation for 8 weeks (G1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Therapeutic SCiP™ therapy for another 8 weeks (G2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham stimulation followed by therapeutic SCiP™ therapy for 8 weeks (G1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Activity-based neurorehabilitation therapy (ABNT) 2 days/week for both groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified Ashworth Scale (secondary outcome)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Frequency and severity of adverse events
Number of subjects: 60
Study: 37564743

Group type: EXPERIMENTAL
Intervention: RBL (Live-Jslm)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 37564986

Group type: EXPERIMENTAL
Intervention: N11005 (300 IU, p.o.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Novolin R (0.1 IU/Kg, i.h.)
Number of subjects: 12
Study: 37565238

Group type: EXPERIMENTAL
Intervention: Behavior Rating Inventory of Executive Function-Preschool (BRIEF-P) version
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Proxy reports of EF impairment
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Parental socioeconomic level
Number of subjects: 357
Study: 37565290

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37565307

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (antiplatelet agent)
Number of subjects: 11571

Group type: COMPARATOR
Intervention: Metoprolol (antihypertensive agent)
Number of subjects: 11571

Group type: COMPARATOR
Intervention: Chlorthalidone (antihypertensive agent)
Number of subjects: 11571

Group type: COMPARATOR
Intervention: Warfarin (anticoagulant agent)
Number of subjects: 11571

Group type: COMPARATOR
Intervention: Lipid-lowering agents (atorvastatin, fluvastatin, lovastatin, pravastatin, probucol, rosuvastatin)
Number of subjects: 11571
Study: 37565393

Group type: EXPERIMENTAL
Intervention: Trial-related blood sampling (1.6 ± 0.6 mL/kg)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Clinical blood sampling (8.1 ± 5.1 mL/kg)
Number of subjects: 193
Study: 37565541

Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg oral dose
Number of subjects: 8
Study: 37565934

Group type: COMPARATOR
Intervention: Multifaceted implementation intervention
Number of subjects: 42489

Group type: EXPERIMENTAL
Intervention: No intervention
Number of subjects: 42489
Study: 37565964

Group type: EXPERIMENTAL
Intervention: 1-stent strategy
Number of subjects: 345

Group type: COMPARATOR
Intervention: 2-stent strategy
Number of subjects: 345
Study: 37565973

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050
Study: 37565977

Group type: EXPERIMENTAL
Intervention: Highest IL-6 levels
Number of subjects: 374
Study: 37566218

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 11231
Study: 37566253

Group type: EXPERIMENTAL
Intervention: Community-based multidisciplinary group intervention program (10-week duration, including twice-weekly exercise sessions and weekly education sessions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Community-based multidisciplinary group intervention program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 37566295

Group type: EXPERIMENTAL
Intervention: 2MACE score
Number of subjects: 25696
Study: 37566431

Group type: EXPERIMENTAL
Intervention: Enhanced mailed FIT outreach (tailored advance notification via text message or live phone call, plus two automated phone call reminders)
Number of subjects: 27585

Group type: COMPARATOR
Intervention: Standard mailed FIT outreach (mailed FIT and live telephone reminders)
Number of subjects: 27585

Group type: COMPARATOR
Intervention: Standard mailed FIT outreach
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Enhanced program (text message plus automated call reminder)
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Enhanced program (live phone calls plus automated call reminder)
Number of subjects: 27585
Study: 37566449

Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) intervention
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual prenatal care
Number of subjects: 210
Study: 37566578

Group type: EXPERIMENTAL
Intervention: OT infusion at 3.3 mU/min in women with morbid obesity
Number of subjects: 40

Group type: COMPARATOR
Intervention: OT infusion in women with non-obesity and obesity
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: OT infusion in women with obesity
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: OT infusion in women with morbid obesity
Number of subjects: 40
Study: 37566892

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not infected with SARS-CoV-2)
Number of subjects: 0
Study: 37567022

Group type: EXPERIMENTAL
Intervention: Premounted dry-pericardium Vienna Self-Expandable Aortic Valve System
Number of subjects: 10
Study: 37567038

Group type: EXPERIMENTAL
Intervention: Autonomous self-regulation
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Between-persons model
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Within-persons model
Number of subjects: 236
Study: 37567205

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir (600 mg) plus rilpivirine (900 mg) dosed intramuscularly every 2 months
Number of subjects: 687

Group type: COMPARATOR
Intervention: Bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) taken daily
Number of subjects: 687
Study: 37567363

Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: continuous TBS (cTBS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: baseline nonstimulation control session
Number of subjects: 37
Study: 37567391

Group type: EXPERIMENTAL
Intervention: PM-RUF
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: PC-RUF
Number of subjects: 871

Group type: COMPARATOR
Intervention: FP
Number of subjects: 871
Study: 37567614

Group type: EXPERIMENTAL
Intervention: Growth differentiation factor (GDF)-15 measurement
Number of subjects: 2166

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards modelling, Net Reclassification Improvement, decision curve analysis
Number of subjects: 2166
Study: 37567748

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) group: 30 min of gait training using an exoskeleton (ANGEL LEGS M20, Angel Robotics) and 30 min of conventional gait training, total of 20 sessions (60 min/session); 5 sessions a week for 4 weeks.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group: 60 min of conventional gait training, total of 20 sessions (60 min/session); 5 sessions a week for 4 weeks.
Number of subjects: 150
Study: 37567750

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg two times a day
Number of subjects: 5022

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5022
Study: 37567779

Group type: EXPERIMENTAL
Intervention: Recombinant factor IX Fc fusion protein (rFIX-Fc)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Published population PK model
Number of subjects: 37
Study: 37567793

Group type: EXPERIMENTAL
Intervention: CIBM model
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: PulmoSeek Plus model
Number of subjects: 1380
Study: 37568076

Group type: EXPERIMENTAL
Intervention: One-Level ESPB (n=30) with 30 ml 0.25% bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bi-Level ESPB (n=30) with 15 ml 0.25% bupivacaine at T4 and T6 levels
Number of subjects: 60
Study: 37568081

Group type: EXPERIMENTAL
Intervention: Esketamine (ESK) + standard of care (SOC)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo (PBO) + standard of care (SOC)
Number of subjects: 451
Study: 37568128

Group type: EXPERIMENTAL
Intervention: Cluster 4 - healthiest lifestyle pattern (n=302)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Cluster 3 - active and shorter sleepers (n=280)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Cluster 2 - lower activity and longer sleepers (n=388)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Cluster 1 - higher screen time and poorer diet (n=213)
Number of subjects: 1183
Study: 37568154

Group type: EXPERIMENTAL
Intervention: Aceneuramic acid (SA-ER)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 37568158

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (20 g thrice a day for 4 weeks)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (for 4 weeks)
Number of subjects: 174
Study: 37568172

Group type: EXPERIMENTAL
Intervention: Integrated health information technology (HIT) and peer-based support strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer component of the intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIT component of the intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community engagement strategies
Number of subjects: 0
Study: 37568171

Group type: EXPERIMENTAL
Intervention: Film-based interventions for GDM detection and management
Number of subjects: 60
Study: 37568206

Group type: EXPERIMENTAL
Intervention: Technical assistance and support from implementation support practitioners (ISPs)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Virtual learning sessions
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: In-person support from ISPs
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Remote support
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Virtual formats of training and technical assistance
Number of subjects: 150
Study: 37568212

Group type: EXPERIMENTAL
Intervention: Structure Learning training (at least 13 sessions over 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training, never exposed to Structure Learning task)
Number of subjects: 0
Study: 37568216

Group type: EXPERIMENTAL
Intervention: C.S.I. training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional vestibular rehabilitation
Number of subjects: 30
Study: 37568242

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 250

Group type: COMPARATOR
Intervention: Oral midazolam
Number of subjects: 250
Study: 37568381

Group type: EXPERIMENTAL
Intervention: Oral carbohydrate 2 hours before elective cesarean delivery
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard fasting
Number of subjects: 148
Study: 37568391

Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation (PTNS) with duloxetine (30 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Duloxetine (30 mg/day) only
Number of subjects: 64
Study: 37568402

Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Number of subjects: 0
Study: 37568622

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 21 days
Number of subjects: 5
Study: 37568887

Group type: EXPERIMENTAL
Intervention: New urinary biomarkers for renal injury diagnosis in patients treated with ICIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diagnostic methods for renal injury
Number of subjects: 0
Study: 37568975

Group type: EXPERIMENTAL
Intervention: Physiology-guided incremental optimisation strategy (PIOS)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Post-PCI FFR <0.90
Number of subjects: 114
Study: 37569880

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 37570430

Group type: EXPERIMENTAL
Intervention: Educational solutions (360 V, VR, web-based information, psychoeducation)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Natural intervention (absence of intervention)
Number of subjects: 350
Study: 37572086

Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance (560 mg/d)
Number of subjects: 20
Study: 37572581

Group type: EXPERIMENTAL
Intervention: Locally produced fish-based ready-to-use therapeutic food (L-RUTF)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard milk-based ready-to-use therapeutic food (S-RUTF)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both L-RUTF and S-RUTF
Number of subjects: 121
Study: 37572618

Group type: EXPERIMENTAL
Intervention: PNE + exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: exercise alone
Number of subjects: 30
Study: 37572646

Group type: COMPARATOR
Intervention: Serpin family C member 1 (SERPINC1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fetuin B (FETUB)
Number of subjects: 0
Study: 37572659

Group type: EXPERIMENTAL
Intervention: ChAd63-MVA RH5 vaccine
Number of subjects: 0
Study: 37572785

Group type: EXPERIMENTAL
Intervention: Cre8 amphilimus-eluting stent
Number of subjects: 2107

Group type: COMPARATOR
Intervention: SYNERGY everolimus-eluting stent
Number of subjects: 2107

Group type: EXPERIMENTAL
Intervention: Personalized duration of DAPT (based on DAPT score)
Number of subjects: 2107

Group type: COMPARATOR
Intervention: Standard duration of DAPT (12 months)
Number of subjects: 2107
Study: 37572891

Group type: EXPERIMENTAL
Intervention: VBX stent
Number of subjects: 73
Study: 37573155

Group type: EXPERIMENTAL
Intervention: 20 mA electrical stimulus
Number of subjects: 31

Group type: COMPARATOR
Intervention: Behavioural Pain Scale
Number of subjects: 31
Study: 37573292

Group type: EXPERIMENTAL
Intervention: 0.1% cymenol mouthwash for eight days (test group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo mouthwash for four days followed by 0.1% cymenol mouthwash for four days (test group B)
Number of subjects: 50
Study: 37573322

Group type: EXPERIMENTAL
Intervention: CR500® treatment applied topically twice a week for 4 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CR500® treatment
Number of subjects: 35
Study: 37573339

Group type: EXPERIMENTAL
Intervention: Machine learning-based assessment of features derived from clinical, neurologic, and neuropsychological examinations, cognitive reserve estimation, depression evaluation, personality traits assessment, APOE and BDNF genotyping, electroencephalography, event-related potential recording, and lumbar puncture for Aβ measurement.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning application to predict Alzheimer's Disease in patients with SCD.
Number of subjects: 0
Study: 37573366

Group type: EXPERIMENTAL
Intervention: Elevated GFAp at follow-up 3-6 months after ICU discharge
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: GFAp levels in patients experiencing different dimensions of fatigue
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: NfL concentration at follow-up
Number of subjects: 57
Study: 37573421

Group type: EXPERIMENTAL
Intervention: Weekly multi-disciplinary team-based case consultation and peer-to-peer sharing of emerging best practices (teleECHO) with monthly interactive webinars and quarterly short courses
Number of subjects: 856

Group type: COMPARATOR
Intervention: Monthly interactive webinars and quarterly short courses
Number of subjects: 856
Study: 37573428

Group type: EXPERIMENTAL
Intervention: Multi-component behavior change technique (BCT) intervention
Number of subjects: 42
Study: 37573534

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) plus lurasidone (NRX-101)
Number of subjects: 22

Group type: COMPARATOR
Intervention: lurasidone alone
Number of subjects: 22